Exelixis (EXEL) Cash from Financing Activities (2010 - 2026)
Exelixis' (EXEL) quarterly Cash from Financing Activities came in at -$457.1 million in Q2 2026, down 55.05% year-on-year from -$1.0 billion in Q2 2025, and down 79.56% quarter-over-quarter from -$254.6 million in Q1 2026.
Exelixis (EXEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Exelixis' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$457.1 million for Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 55.05% year-over-year to -$457.1 million in Q2 2026; TTM through Apr 2026 was -$1.1 billion, a 53.04% decrease from a year earlier, with the FY2026 full-year figure at -$969.6 million, down 54.2% from the prior year.
- Cash from Financing Activities slipped to -$457.1 million in Q2 2026 per EXEL's latest filing, from -$254.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $5.7 million in Q3 2024 and bottomed at -$457.1 million in Q2 2026.
- The 5-year median for Cash from Financing Activities is -$184.0 million (2024), against an average of -$153.0 million.
- Biggest YoY gain for Cash from Financing Activities was 2137.07% in 2023; the steepest drop was 10678.85% in 2023.
- Year by year, Cash from Financing Activities stood at -$2.0 million in 2022, then sank by 10193.21% to -$206.2 million in 2023, then surged by 102.76% to $5.7 million in 2024, then plunged by 1923.38% to -$103.9 million in 2025, then plunged by 340.12% to -$457.1 million in 2026.
- Per Business Quant, the three latest EXEL Cash from Financing Activities figures stand at -$457.1 million (Q2 2026), -$254.6 million (Q1 2026), and -$103.9 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | -457.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -457.11 Mn |
| Apr 3, 2026 | -457.11 Mn |
| Jan 2, 2026 | -254.57 Mn |
| Jan 2, 2026 | -254.57 Mn |
| Oct 3, 2025 | -103.86 Mn |
| Oct 3, 2025 | -103.86 Mn |
| Jul 4, 2025 | -316.34 Mn |
| Jul 4, 2025 | -316.34 Mn |
| Apr 4, 2025 | -294.82 Mn |
| Apr 4, 2025 | -294.82 Mn |
| Jan 3, 2025 | -188.03 Mn |
| Jan 3, 2025 | -188.03 Mn |
| Sep 27, 2024 | 5.70 Mn |
| Sep 27, 2024 | 5.70 Mn |
| Jun 28, 2024 | -262.42 Mn |
| Jun 28, 2024 | -262.42 Mn |
| Mar 29, 2024 | -184.05 Mn |
| Mar 29, 2024 | -184.05 Mn |
| Dec 29, 2023 | -206.17 Mn |
| Dec 29, 2023 | -206.17 Mn |